Bromide

Bromide

SCHEMBL8586767

CCCC[N+](CCCC)(CCCC)CCCCCC[N+](CCCC)(CCCC)CCCC.[Br-].[Br-]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.93
▸ TP53 P04637 1/20 0.93
▸ CYP3A4 P08684 1/20 0.93
▸ ALOX15 P16050 1/20 0.93
▸ TSHR P16473 1/20 0.93
▸ ALOX12 P18054 1/20 0.93
▸ SMN1; SMN2 Q16637 1/20 0.93
▸ HIF1A Q16665 1/20 0.93
▸ HSD17B10 Q99714 1/20 0.93
▸ SLC22A1 O15245 3/20 0.87
▸ SLC22A2 O15244 1/20 0.80
▸ DNM1 Q05193 7/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5084980 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5085227 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5087210 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL2733876 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5088202 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL1347880 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL3028771 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5085187 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL1507558 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL3916850 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043636-B2 Method for producing triarylorganoborates COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2024-07-23 — — US disclosed
US-20240002409-A1 METHOD FOR PRODUCING TRIARYLORGANOBORATES COVESTRO DEUTSCHLAND AG (DE) 2024-01-04 — — US disclosed
US-11760765-B2 Method for producing triarylorganoborates COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2023-09-19 — — US disclosed
US-11078218-B2 Process for the production of triaryl organoborates COVESTRO DEUTSCHLAND AG (DE) 2021-08-03 — — US disclosed
US-20190276479-A1 PROCESS FOR THE PRODUCTION OF TRIARYL ORGANOBORATES COVESTRO DEUTSCHLAND AG (DE) 2019-09-12 — — US disclosed
US-5804525-A BINARY CATALYST OF TERTIARY ORGANIC AMINE AND PHASE TRANSFER CATALYST GENERAL ELECTRIC COMPANY (US) 1998-09-08 — — US disclosed
US-5739257-A INTERFACIAL POLYMERIZATION OF A DIHYDROXY COMPOUND AND PHOSGENE IN THE PRESENCE OF METHYLTRIBUTYLAMMONIUM HALIDE OR HEXABUTYLBUTYLENEDIAMMONIUM HALIDE GENERAL ELECTRIC COMPANY (US) 1998-04-14 — — US disclosed
US-5519105-A CONDENSATION POLYMERIZATION IN THE PRESENCE OF PHASE TRANSFER CATALYST GENERAL ELECTRIC COMPANY (US) 1996-05-21 — — US disclosed
EP-0682055-A2 Binary catalyst for making aromatic polycarbonates GENERAL ELECTRIC COMPANY (US) 1995-11-15 — — EP disclosed
US-4933469-A Method for preparing oxybisphthalimides GENERAL ELECTRIC COMPANY (US) 1990-06-12 — — US disclosed
US-4585638-A Synthesis of crystalline silicate ZSM-5 MOBIL OIL CORPORATION (US) 1986-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002409-A1 METHOD FOR PRODUCING TRIARYLORGANOBORATES KMO, COASY, CYP3A4 ALDH1A1 2226/4885TP53 3652/4885CYP3A4 3/4885
US-11078218-B2 Process for the production of triaryl organoborates OR10J3, CYP4F3, CYP4B1 ALDH1A1 3058/4885TP53 4158/4885CYP3A4 11/4885
US-12043636-B2 Method for producing triarylorganoborates KMO, COASY, CYP3A4 ALDH1A1 2226/4885TP53 3652/4885CYP3A4 3/4885
US-11760765-B2 Method for producing triarylorganoborates CYP3A4, CYP3A43, CYP4B1 ALDH1A1 1623/4885TP53 3682/4885CYP3A4 1/4885
US-20190276479-A1 PROCESS FOR THE PRODUCTION OF TRIARYL ORGANOBORATES CYP1B1, CYP3A4, CYP4B1 ALDH1A1 1943/4885TP53 3930/4885CYP3A4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback